ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2023
Estimates of the global burden of Congenital Rubella Syndrome, 1996-2019.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Measles and Rubella Elimination Trends in the WHO Eastern Mediterranean Region, 2023-2024: Progress and Recent Epidemiological Shifts.Vaccines · 2026Article
- Progress Toward Rubella and Congenital Rubella Syndrome Elimination - Worldwide, 2012-2024.MMWR. Morbidity and mortality weekly report · 2026Article
- Bilateral Deep Vein Thrombosis in an Adolescent with Congenital Rubella Syndrome: A Case Report.Research in heart yield and translational medicine · 2026Article
- Measles and rubella: From global health challenges to advancements in molecular diagnostics in the elimination era.Molecular therapy. Nucleic acids · 2025Review
- Gene Expression Factors Associated with Rubella-Specific Humoral Immunity After a Third MMR Vaccine Dose.Viruses · 2025Article
- Estimated Current and Future Congenital Rubella Syndrome Incidence with and Without Rubella Vaccine Introduction - 19 Countries, 2019-2055.MMWR. Morbidity and mortality weekly report · 2025Article
- The evolving landscape of rubella in the WHO African Region.The Pan African medical journal · 2025Article
- A case of congenital rubella syndrome and epidemiology of related cases in China, 2014-2023.Human vaccines & immunotherapeutics · 2024Article
- Assessment of Simplified Surveillance for Congenital Rubella Syndrome in Sudan, 2014-2017.Vaccines · 2024Article
- Article
- Measles-Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations.Vaccines · 2024Article
- Article
- Article
- Congenital Rubella Syndrome Does Not Increase with Introduction of Rubella-Containing Vaccine.Vaccines · 2024Article
- Serosurveillance for Measles and Rubella.Vaccines · 2024Review
- Evolution and Contribution of a Global Partnership against Measles and Rubella, 2001-2023.Vaccines · 2024Article
- Review
- Accelerating Global Measles and Rubella Eradication-Saving Millions of Lives, Preventing Disability, and Averting the Next Pandemic.Vaccines · 2024Article
- Pregnant women and measles: we need to be vigilant during outbreaks.EClinicalMedicine · 2024Review
- Seroprevalence for Measles, Varicella, Mumps and Rubella in the Trainee Obstetric Population: A Survey in Southern Italy.Vaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMany countries introduced rubella-containing vaccination (RCV) after 2011, following changes in recommended World Health Organization (WHO) vaccination strategies and external support. We evaluated the impact of these introductions.
methodsWe estimated the country-specific, region-specific, and global Congenital Rubella Syndrome (CRS) incidence during 1996-2019 using mathematical modeling, including routine and campaign vaccination coverage and seroprevalence data.
resultsIn 2019, WHO African and Eastern Mediterranean regions had the highest estimated CRS incidence (64 [95% confidence intervals (CI): 24-123] and 27 [95% CI: 4-67] per 100,000 live births respectively), where nearly half of births occur in countries that have introduced RCV. Other regions, where >95% of births occurred in countries that had introduced RCV, had a low estimated CRS incidence (<1 [95% CI: <1 to 8] and <1 [95% CI: <1 to 12] per 100,000 live births in South-East Asia [SEAR] and the Western Pacific [WPR] respectively, and similarly in Europe and the Americas). The estimated number of CRS births globally declined by approximately two-thirds during 2010-2019, from 100,000 (95% CI: 54,000-166,000) to 32,000 (95% CI: 13,000-60,000), representing a 73% reduction since 1996, largely following RCV introductions in WPR and SEAR, where the greatest reductions occurred.
conclusionsFurther reductions can occur by introducing RCV in remaining countries and maintaining high RCV coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.